Gene editing for heart disease: Verve kicks off landmark base editing trial

Amber Tong

Verve Therapeutics has dosed the first patient with its lead cardiovascular drug, marking a major milestone for the next-gen gene editing technique known as base …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Gene editing for heart disease: Verve kicks off landmark base editing trial

Amber Tong

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

FDA says Ozempic, Wegovy shortage is over

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Gene edit­ing for heart dis­ease: Verve kicks off land­mark base edit­ing tri­al

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Gene editing for heart disease: Verve kicks off landmark base editing trial